Zealand Pharma A/S (OTCPK:ZLDPF) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET
Company Participants
Adam Lange – Vice President, Investor Relations
Adam Steensberg – President & Chief Executive Officer
David Kendall – Chief Medical Officer
Henriette Wennicke – Chief Financial Officer
Eric Cox – Chief Commercial Officer
Conference Call Participants
Michael Novod – Nordea
Andy Hsieh – William Blair
Prakhar Agrawal – Cantor Fitzgerald
Chiara Montironi – Van Lanschot Kempen
Charlie Haywood – Bank of America
Shan Hama – Jefferies
Ollie Burrow – Goldman Sachs
Adam Lange
Thank you to everyone for joining us today to discuss Zealand Pharma’s results for the First Three Months of 2025. You can find the related company announcements on our website at zealandpharma.com.
As described on slide 2, I caution listeners that during this call, we will be making forward-looking statements that are subject to risks and uncertainties.
Turning to slide 3 and the agenda. With me today are the following members of Zealand Pharma’s management team. Adam Steensberg, President and Chief Executive Officer; Henriette Wennicke, Chief Financial Officer; and David Kendall, Chief Medical Officer. All speakers will be available for the Q&A session along with Eric Cox, Chief Commercial Officer.
Moving to slide 4, I will turn the call over to Adam Steensberg, President and CEO.
Adam Steensberg
Thank you, Adam, and thanks to everyone for joining today. Zealand has never been in a stronger position than we are today financially, organizationally and in terms of our clinical development pipeline.
Our vision is to become a key player in the future management of obesity and we now have the strongest possible foundation to realize this vision. We have a differentiated mid to late stage obesity pipeline and recently entered a historic and transformative collaboration with Roche on petrelintide.
The agreement
